A 13.2 mg epinephrine intranasal spray demonstrates comparable pharmacokinetics, pharmacodynamics, and safety to a 0.3 mg epinephrine autoinjector.

Journal: The journal of allergy and clinical immunology. Global
Published Date: Dec 12, 2023

Abstract

BACKGROUND: Recent acute anaphylaxis guideline updates have identified remaining unmet needs based on currently available therapeutic options as a critical focus.

Authors

  • David A Dworaczyk
    Bryn Pharma LLC, Raleigh, NC.
  • Allen L Hunt
    Celerion Inc, Lincoln, Neb.
  • Mike Di Spirito
    Celerion Inc, Lincoln, Neb.
  • Mary Lor
    Celerion Inc, Lincoln, Neb.
  • Kenneth L Dretchen
    Mesa Science Associates, Frederick, Md.
  • Michael J Lamson
    Allucent, Cary, NC.
  • Jonathan Pollock
    Celerion Inc, Lincoln, Neb.
  • Thelma Ward
    Celerion Inc, Lincoln, Neb.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals